AMS (American Medical Systems) closes TherMatrx deal:
This article was originally published in Clinica
American Medical Systems (AMS) has completed its acquisition of TherMatrx, the developer of TMx2000, an in-office treatment for benign prostatic hyperplasia. The technology was originally developed by BSD Medical, a Salt Lake City company with substantial holdings in TherMatrx. AMS of Minnetonka, Minnesota, first announced its intention to purchase TherMatrx, which includes all of BSD's holdings in the company, in June (see Clinica No 1113, p 13).
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.